Trial Profile
A Phase II Study, Multicenter, to Evaluate the Efficacy and Safety of the Combination of Reirradiation - Erbitux in Subjects Previously Irradiated and With a Local Recurrent Inoperable Squamous Cell Cancer of the Head and Neck
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2017
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 02 Dec 2016 Status changed from recruiting to completed.
- 18 Nov 2010 New trial record